Active Ingredient(s): Elexacaftor + Ivacaftor + Tezacaftor
FDA Approved: * October 21, 2019
Pharm Company: * VERTEX PHARMS INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Trikafta Overview

Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta (US) and Kaftrio (Europe), is a fixed-dose combination medication used in those that have cystic fibrosis with a f508del mutation.[1] It is made up of a combination of elexacaftor, tezacaftor, and ivacaftor.[1] It was approved for medical use in the United States in 2019.[1][2][3] In June 2020, the Committee for Medicinal Products for Human Use ...

Read more Trikafta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Trikafta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Elexacaftor + Ivacaftor + Tezacaftor
  • Tablet: 100mg,75mg,50mg + 150mg, 50mg,37.5mg,25mg + 75mg
  • Tablet, Tablet: 100mg,75mg,50mg + N/a,150mg,n/a
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Trikafta: (2 results)

Sorted by National Drug Code
  • 51167-106 TrikaftaTrikafta Kit by Vertex Pharmaceuticals Incorporated
  • 51167-331 TrikaftaTrikafta Kit by Vertex Pharmaceuticals Incorporated

Drugs with one or more similar ingredients: (7 results)